You might like
In meta-analysis, moderate-certainty that 47% of wet AMD pts had retinal fluid after 2y of anti-VEGF treatment. Cure-models predict that up to 18% of patients may never achieve fluid resolution @dominicyap_ @BenjaminKJTan @snec_seri @NUSMedicine @mysgh ow.ly/cCFo50USqRb
Finally, a honest, plausible academia-driven and patient-centred analysis on IO biomarkers without secondary, for-profit agendas. Great job Dr Leone 🦁 & collaborators across the globe. A 🇸🇬🇮🇹 joint effort. @FilippoPietran4 @JAMAOnc
Meta-analysis of immune checkpoint inhibs as first or second line Rx in pts w/esophageal squamous cancer showed no significant OS benefit w/chemoimmunotherapy vs. chemo alone for pts w/TPS <1%, modest OS benefit w/combined pos score <10. ja.ma/3VZZ66X
How do we understand 2 independent meta-analyses published the same week (Yap et al JAMA Onc 2022 N= 4752; Wu et al JCO 2022 N=2908) evaluating the same question but coming to opposite conclusions?? jamanetwork.com/journals/jamao… pubmed.ncbi.nlm.nih.gov/36473145/
Our recent work was published in JCO. ESCC patients with negative PD-L1 expression can also benefit from the addition of PD-1 antibody to chemo.#Cancer #immunotherapy
The controversy continues. We just published in @JAMAOnc an analysis showing minimum benefit of immunotherapy for low PD-L1 expressing esophageal tumors jamanetwork.com/journals/jamao…, @FengWan25720657 shows the opposite ascopubs.org/doi/10.1200/JC…. are we none the wiser? @FilippoPietran4
Efficacy of ICI in ESCC patients with low PDL1 expression: Our pooled analysis shows there may not be OS benefit in TPS<1% pts. Harmonised biomarkers needed for better pt selection @FilippoPietran4 @sundar__raghav @NickyWongZH @josephjzhao ja.ma/3UIM5xB @JAMAOnc
@Nicholas_Syn @BenjaminKJTan @TeoChongBoon @dominicyap_ @sundar__raghav bmcmedresmethodol.biomedcentral.com/articles/10.11…
CheckMate-649: 🚫 No survival benefit from nivolumab + chemotherapy in CPS 1-4 gastroesophageal adenocarcinoma ➡️ fal.cn/3kBHk #JCO #esocsm #stcsm @josephjzhao
Analysis of data from CheckMate 649, KEYNOTE-062 and KEYNOTE-590 suggest that pts with PD-L1-low advanced-stage gastric/GEJ adenocarcinoma might derived no benefit from the addition anti-PD-1 antibodies to first-line chemotherapy: ascopubs.org/doi/full/10.12… #stcsm #esocsm
Very well done Dr. Joseph J. Zhao & colleagues on conducting this study. All of us have been looking for these KM curves. @JCO_ASCO #JCO #patients with ⬇️ PD-L1 expression è #Gastric #Esophageal #cancers didn’t benefit from ICIs @OncoAlert ascopubs.org/doi/abs/10.120…
No doubt pts with low CPS has less benefit. Hopefully ongoing studies LEAP-015, Attraction-6, chemo+RegoNivo or other agents (zolbetuximab and bemarituzumab) will improve outcomes of these patients
This is innovative and important work in @JCO_ASCO from @sundar__raghav Computational analysis can accurately derive unpublished subgroup results in clinical trials 🤯🤯 ! This approach has the potential to be a game changer! Well done 👏👏 @OncoAlert @VJOncology @myESMO
Pleased to present data that most GI oncologists have been asking for, but not gotten so far: role of Nivolumab in CPS 1-4 gastric cancer. ascopubs.org/doi/full/10.12… Answer: Minimum to none. EMA has restricted approval to only CPS >= 5. What about FDA?
Thanks to my friend @sundar__raghav for this extremely important work. For HER2- #gastric #cancer, immunotherapy is not effective, not only in CPS 0 subgroup, but also in CPS 1-4 and 1-9. For these subgroups, immune-sensitizing strategies are needed!! ascopubs.org/doi/full/10.12…
Pleased to present data that most GI oncologists have been asking for, but not gotten so far: role of Nivolumab in CPS 1-4 gastric cancer. ascopubs.org/doi/full/10.12… Answer: Minimum to none. EMA has restricted approval to only CPS >= 5. What about FDA?
In this meta-analysis of 4,885,518 patients from four observational studies, patients with OSA had approximately 30% higher risk of lung cancer, compared to those without OSA. @yaohao_teo @yaoneng_teo @dominicyap_ atsjournals.org/doi/10.1513/An… @AnnalsATS
United States Trends
- 1. Good Wednesday 22.7K posts
- 2. #hazbinhotelseason2 38.7K posts
- 3. PancakeSwap BNB Chain 2,249 posts
- 4. #wednesdaymotivation 3,357 posts
- 5. ADOR 53.1K posts
- 6. Hump Day 9,458 posts
- 7. #Wednesdayvibe 1,722 posts
- 8. Happy Hump 5,822 posts
- 9. USDT 113K posts
- 10. Northern Lights 50.7K posts
- 11. #HazbinHotelSpoilers 4,374 posts
- 12. Hanni 15.4K posts
- 13. #huskerdust 10.3K posts
- 14. StandX 2,511 posts
- 15. Vaggie 7,758 posts
- 16. MIND-BLOWING 34.3K posts
- 17. Jack Schlossberg 2,220 posts
- 18. Wike 253K posts
- 19. H-1B 43.8K posts
- 20. SPECTACULAR 25.7K posts
Something went wrong.
Something went wrong.